GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Shares Outstanding (EOP)

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Shares Outstanding (EOP) : 680 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Swedish Orphan Biovitrum AB's shares outstanding for the quarter that ended in Mar. 2024 was 680 Mil.

Swedish Orphan Biovitrum AB's quarterly shares outstanding increased from Dec. 2023 (680 Mil) to Mar. 2024 (680 Mil). It means Swedish Orphan Biovitrum AB issued new shares from Dec. 2023 to Mar. 2024 .

Swedish Orphan Biovitrum AB's annual shares outstanding increased from Dec. 2022 (620 Mil) to Dec. 2023 (680 Mil). It means Swedish Orphan Biovitrum AB issued new shares from Dec. 2022 to Dec. 2023 .


Swedish Orphan Biovitrum AB Shares Outstanding (EOP) Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Shares Outstanding (EOP) Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 616.22 617.47 617.99 619.82 679.51

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 621.07 621.75 678.88 679.51 679.74

Competitive Comparison of Swedish Orphan Biovitrum AB's Shares Outstanding (EOP)

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) falls into.



Swedish Orphan Biovitrum AB Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Swedish Orphan Biovitrum AB Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Headlines